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Endophytic and epiphytic microbes
as “sources” of bioactive agents
David J. Newman 1* † and Gordon M. Cragg 2 †
1 Retired, Wayne, PA, USA, 2 Retired, Bethesda, MD, USA
Beginning with the report by Stierle and Strobel in 1993 on taxol(R) production by an
endophytic fungus (Stierle et al., 1993), it is possible that a number of the agents now
used as leads to treatments of diseases in man, are not produced by the plant or
invertebrate host from which they were first isolated and identified. They are probably
the product of a microbe in, on or around the macroorganism. At times there is an
intricate “dance” between a precursor produced by a microbe, and interactions within
the macroorganism, or in certain cases, a fungus, that ends up with the production of a
novel agent that has potential as a treatment for a human disease. This report will give
examples from insects, plants, and marine invertebrates.
Keywords: endophyte, epiphyte, natural product sources, ultured microbes, novel sources
Introduction
Due to the differences in timing of reports in the literature, we have attempted to identify when
the first report of endo- or epiphytic microbes being involved in the production of a particular
compound, or class of compounds, isolated from a host organism was reported. As mentioned in
the abstract, we will cover, albeit only superficially in some cases, developments from a descriptive
aspect, but essential citations will be given so that interested readers can investigate further.
In addition to the three sources given in the abstract, we will also comment on some very
interesting, relatively recent relationships between fungi and bacteria, a relationship that is not
usually recognized.
Marine Sourced Materials
In the early 1980s, Frincke and Faulkner (1982) from the Scripps Institution of Oceanography
in California investigating the compounds produced (better terms today might be “found in”
or “isolated from”) by sponges in the Eastern Pacific off the West coast of California, isolated,
and purified the compound known as renieramycin A (Figure 1; 1). Inspection of the structure
of this molecule showed that the base structure closely resembled a series of known antitumor
agents that had been isolated from fermentation of a terrestrial microbe, the saframycins A–
C (Figure 1; 2–4). These compounds had been reported (Arai et al., 1977) from Streptomyces
lavendulae initially as antibiotics, and later as having antitumor activity (Arai et al., 1980).
Faulkner was not able to determine the antitumor activity of his isolate due to the very small
amount of material isolated. Twenty years later, the Fusetani group in Tokyo (Nakao et al., 2004)
reported the same material from an entirely different sponge, a Neopetrosia species using an
antileishmanial assay rather than an antitumor assay; thus demonstrating that the same molecule
may well have quite different activities dependent upon the bioassay used for following the
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FIGURE 1 | Compounds from Marine-sourced Microbes.
isolation. It may be relevent at this point to make the point that
most of the marine-derived materials reported in the literature
were identified by bioactivity driven isolation techniques.
This series of discoveries could be considered the beginnings
of a tsunami of reports over the last 30 plus years, that now have
led to the possibility that the majority of compounds isolated
from multicellular marine invertebrates involve production
by a microorganism. We have used the term multicellular
to differentiate from single celled organisms, though even
that definition might be incorrect as knowledge evolves. The
production may have, but equally may not have an interaction
with the nominal “host producer.”
We will now give some specific examples of what we have just
described; these will to some extent be in chronological order by
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discovery of the original compound, but the “proof” (direct or in
some cases circumstantial) has occurred at differing time points
from the original report(s).
Dolastatins
This collection of linear and cyclic peptides with very unusual
amino acids in their structures, were first described by the Pettit
group at Arizona State University working in conjunction with
the National Cancer Institute, using the NCI’s bioactive assays
initially, and were shown to have potent antitumor activities. Due
to the very limited abundance of the nudibranch fromwhich they
were first isolated, once the initial structures were determined, the
molecules had to be synthesized chemically in order to advance
them into preclinical development, and then into clinical trials as
an antitumor agent in the case of dolastatin 10 (Figure 1; 5). The
full details of the initial discoveries and synthetic methodologies
were well described by Flahive and Srirangam (2012).
In the late 1990s to early 2000s, the Hawaiian group led by
Moore reported that the probable producer of these molecules
was a cyanobacterium on which the nudibranch grazed. Thus,
dolastatins 3, 10, and 12 were reported from cyanobacteria
(Luesch et al., 2002) and although not formally reported in the
literature, Dr. Valerie Paul (then at the University of Guam
Marine Station) observed D. auricularia (the nudibranch from
which the dolastatins were originally isolated) grazing upon
cyanobacteria containing dolastatins, She subsequently isolated
dolastatins from both the nudibranch and the cyanophyte (Paul,
personal communication).
Although none of the naturally occurring dolastatins
successfully transitioned from discovery to a clinically approved
drug, an analog that was based upon the dolastatin 10 structure
has become an approved antitumor drug. The modified
dolastatin now known as vedotin, based on auristatin E
(Figure 1; 6), was used as a warhead on a monoclonal antibody
directed against Hodgkins lymphoma. This combination, known
as Adcetris(R) (Figure 1; 7) was approved in 2011 by the US
FDA, but would never have been synthesized in the absence
of the knowledge of the dolastatin structures. As of early 2014
there were 21 variations (different combinations of auristatin
E or F and different MAbs/linkers) in clinical trials or close to
entering them (Newman and Cragg, 2014). Currently (March
2015) there are nine combinations of monoclonal antibodies
linked to auristatin E in Phase I to Phase III clinical trials, and
two using auristatin F in Phase I trials against cancer targets. The
“drop-out” of molecules at the Phase I level is very frequent, so
the difference in numbers is not unusual.
Didemnins
The first marine-derived agent to go into clinical trials for cancer
was the cyclic depsipeptide didemnin B (Figure 1; 8). This was
one of a number of very similar compounds reported by the
Rinehart group at the University of Illinois in the early 1980s
from the tunicate Trididemnum solidum. As with the dolastatins,
a total synthesis was necessary in order to obtain enoughmaterial
for preclinical and clinical trials, and this was reported in 1987
(Rinehart et al., 1987).
The compound progressed through to Phase II clinical trials
but did not proceed beyond this level due to a combination of
lack of activity and toxicity. Full details of the synthetic methods
and the clinical development was published by Lee et al. (2012).
What was a major discovery as to the source came from two
papers, one from Japan published in 2011 (Tsukimoto et al., 2011)
demonstrating that a free-living microbe from Japanese waters
produced didemnin B, and the other reported by a Chinese-
Saudi-USA consortium giving the full genomic sequence of
the didemnin gene cluster from a microbe collected in the
Red Sea (Xu et al., 2012). This later paper demonstrated the
temporal production of the didemnins via previously suggested
intermediates in “real time” by using mass spectrometric
techniques on the growing microbe (Xu et al., 2012). The free-
living microbes in both cases were from the unusual genus,
Tistrella with T. mobilis in the first report and T. bauzanensis and
T. mobilis in the second. Thus, there is no doubt that these are the
source of these depsipeptides.
A very close chemical relative, aplidine was isolated from the
same tunicate differing only by two hydrogen atoms on the side
chain, with a pyruvyl instead of a lactyl group as in didemnin B.
This compound was later found in the Mediterranian tunicate
Aplidium albus by PharmaMar scientists, and is currently
in multiple clinical trials from Phase II to Phase III with
PharmaMar. An MAA (equivalent to the US NDA) filing is due
in 2015.
Ecteinascidin 743
In the 1969/1970 time frame, Sigel and colleagues reported on
the antitumor activity of an ethanolic extract of the tunicate
Ecteinascidia turbinata [published in book form in 1970 (Sigel
et al., 1970)].The active compounds, all with the base skeleton of
the napthyridinomycin alkaloids exemplified by the saframycins
(tetrahydroisoquinoline alkaloids), were then isolated from the
same Caribbean tunicate E. turbinata 17 years later as a complex
of similar molecules. The first formal report was by Holt in
his PhD thesis in 1986 (Holt, 1986). This was followed in 1990
by two simultaneous reports, one from the Rinehart group
at the University of Illinois (Rinehart et al., 1990) and the
other from the Wright group at Harbor Branch Oceanographic
Institution (Wright et al., 1990). The molecules were licensed
to the Spanish company PharmaMar for preclinical and clinical
development, being approved in the EU in 2007 as Yondelis(R) for
the treatment of sarcoma. In November, 2014 an NDA was filed
in the USA by Janssen (who licensed the molecule) for the same
indication. The full story of the production by aquaculture and
then semisynthesis was reported by Cuevas and Francesch (2009)
and Cuevas et al. (2012), and should be consulted for further
information.
Although the production of the molecule for clinical use
was via semisynthesis from cyanosafracin (a cyano derivative of
a microbial metabolite), there were suggestions that an as yet
uncultured bacterium, Candidatus Endoecteinacidia frumentenis
(AY054370), was involved in the production of these molecules.
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This organism was found in ecteinascidin 743 producing E.
turbinata collected in both the Caribbean and the Mediterranean
(Moss et al., 2003; Perez-Matos et al., 2007). These reports,
coupled to the suggestions by Piel (2006) as to how to utilize
bacterial symbionts from invertebrates, led to the confirmation
of these suggestions by Rath et al. (2011).
By using the known gene clusters of the saframycin (Li
et al., 2008) and safracin (Velasco et al., 2005) metabolites as
markers, the “contig” encoding the NRPS biosynthetic enzymes
involved in trabectedin production was identified as well as the
producing organism. This was the γ-proteobacterium known
as Candidatus Endoecteinascidia frumentensis (AY054370),
previously suggested as the actual producer even though not yet
cultured. An example of what can now be done using advanced
genomic techniques.
Candidatus Entotheonella
Metabolite Production in the Sponge Theonella
swinhoei
The work reported in the journal Nature by the Piel group
early in 2014 on the production of metabolites from the
yellow or “Y” biotype of this sponge, effectively laid to
rest circumstantial arguments about sponge metabolites being
derived from microbes in the sponge (Wilson et al., 2014). In a
tour-de-force, this group isolated two phylotypes of the candidate
genus Entotheonella with genomes greater than nine megabases
and multiple distinct biosynthetic gene clusters from this sponge,
via cell disruption and FACS sorting into reaction wells with a
single cell per well. From genomic studies, 31 of the reported 32
polyketide metabolites (most of which have reported bioactivity)
previously isolated from this sponge variant were attributed to
a single phylotype. These as yet uncultured bacteria are widely
distributed in sponges and belong to an environmental taxon
proposed as the candidate phylum Tectomicrobia.
Calyculin Production in Discodermia calyx
Almost simultaneously with the Theonella swinhoei results, a
similar series of experiments, but looking at the production of
the well-known phosphatase inhibitor, calyculin (Figure 1; 9)
isolated from the sponge Discodermia calyx, demonstrated that
the molecule was in fact produced by the symbiotic bacterium,
Candidatus Entotheonella sp. A (Wakimoto et al., 2014).
The potential for use of these gene clusters in the production
of previously known and unknownmetabolites is discussed in the
recent papers by Helfrich et al. (2014) and Guo et al. (2015) which
should be consulted for examples. These are not the only papers
dealing with this subject but they are amongst the most recent.
Plants and Endophytes/Epiphytes
From our perspective, the situation with plants, and whether
or not microbes have anything to do with the metabolites
found from studying compounds isolated from plant materials,
is now roughly at the same stage of “proof” as the situation
which existed 2 or 3 years after the initial discovery by
Faulkner’s group of the renieramycins (vide infra). This applies
to compounds isolated from plants either by using bioactivity-
driven isolation, or by what used to be known as “grind
and find/phytochemical investigations,” where compounds were
isolated and then sometimes the purified chemical entities would
be investigated pharmacologically.
The major difference is that the discovery of renieramycin
closely followed the beginning of the systematic discovery of
metabolites in organisms from the marine environment, whereas
roughly two centuries had elapsed between pure compound
discovery from terrestrial plants, dating approximately from
Seturner’s identification of purified morphine in 1817, and the
discovery of potential microbial involvement in plant metabolite
production. We should note that there are conflicting reports
as to the dates recorded in the literature for the isolation
of morphine, which range from 1803 to 1817, but the full
chronology showing that the initial 1803-04 report was not the
isolation of an alkaloid (basic) but rather an acidic compound
(possibly meconic acid) has been given by Newman and Cragg
in 2010, and should be consulted for the full story (Newman and
Cragg, 2010).
In 2003, Strobel suggested that every one of the approximately
350,000 species of vascular plants on Earth serves as a host for at
least one endophytic microbe, organisms (often fungal in nature)
that live within the tissues of the plant but do not cause any
deleterious effect on the plant host. This suggestion was possibly
due to his initial work on the microbial production of taxol(R) by
an endophytic fungus originally isolated from the inner tissues
of the taxol-producing Taxus brevifolia tree and reported in 1993
(Stierle et al., 1993).
Does this comment mean that plants do not produce
secondary metabolites but that microbes are involved in every
facet of production? No, this is not our contention at this state
of knowledge.
What we will show in this section is that in the case of
some well-known compounds with a variety of pharmacological
activities, the actual producers are in some cases a microbe (often
fungal in origin), and in other cases, microbes are involved but
variable results are obtained on fermentation of the microbe at
this stage of knowledge.
In some cases, there are reports of isolated microbes not
known to be involved with a plant producing what were thought
to be “plant-only” compounds such as chalcones. An excellent
example would be the work reported by Moore et al. in 2002
demonstrating the presence of Type III PKS systems in the
marine bacterium Streptomyces maritimus (Moore et al., 2002).
Taxol(R) from Endophytes
As mentioned above, the report on the potential of isolated fungi
to produce secondary metabolites that were in low quantity in
the host plant, caused a substantial number of natural product
chemists and biologists to start investigating, not only the
production of taxol(R), but also to look at other pharmacologically
interesting molecules which will be considered in subsequent
sections.
In the case of taxol(R) there have been many publications over
the last 20 years where investigators have demonstrated that low
levels of taxol(R) could be obtained from many endophytic fungi
isolated, not just from Taxus species but from a multiplicity of
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plants, even including hazelnut producing plants, first reported
in 2000 (Service, 2000).
In the case of the hazelnut, much more information plus
transcriptome analyses were published by Ma et al. (2013),
demonstrating the genes necessary for taxol(R) biosynthesis.
Recently, Yang et al. identified paclitaxel production in
an endophyte, Penicillium aurantiogriseum from hazel and
identified the gene clusters involved, demonstrating evolution
of the biosynthetic machinery in this Penicillium species
independent of the plant host (Yang et al., 2014). In this
case, there is little doubt that the fungus produces the
compound.
Although one paper was recently published that claimed not
to be able to identify any taxane biosynthesis in three fungi
(including the original isolate from Strobel, though obtained
from a repository, not the original investigators) and two that
they isolated themselves from Taxus species (Heinig et al.,
2013), many other investigators have been able to obtain
genetic information including the full biosynthetic pathway from
endophytic fungi.
The following recent papers should be consulted for the
results demonstrating production of taxol(R) by a variety of
endophytic fungi including identification of the relevant genetic
machinery in the fungi investigated (Zaiyou et al., 2013; Kusari
et al., 2014a,b). These papers demonstrate the potential, and
the Soliman and Raizada paper in 2013 is of significant interest
because it points out that the experiments utilized in all
previous work relied upon axenic culture methods, whereas
in the plant there would be significant interaction/competition
between different microbes. They demonstrated increased yields
when competitive fungi and other agents were introduced into
the cultures, a phenomenon known to “induce” expression
of cryptic gene clusters (Soliman and Raizada, 2013). One
excellent example of this type of response is the report
where suspension cells of Taxus chinensis var mairei were
co-cultured in a bioreactor with its endophytic microbe,
Fusarium mairei with a doubling of the yield of taxol(R)
(Li et al., 2009).
Thus, we consider that there is sufficient evidence to implicate
fungal endophytes in the production of taxol(R) in plants but
the fungi so far investigated, except in the case of Penicillium
and hazel, may not be the only “player(s)” in the system, since
as mentioned above the genes required for taxol(R) biosynthesis
may well require activation of cryptic clusters in the interacting
microbe(s). Many examples, though not from this system, have
been published (Bertrand et al., 2014; Whitt et al., 2014), and
recently Kusari et al., published a paper that covered interactions
across a variety of kingdoms and phyla relevant to this thesis
(Kusari et al., 2013).
One consistent comment made by reviewers/authors arguing
against fungal/microbial involvement in taxol(R) production in
plants is that a major source of this compound for commercial
use is plant tissue culture. However, to the authors’ knowledge,
there are no axenic plant tissue culture processes for any “plant-
derived metabolite.” Thus, until an axenic (not surface sterilized
or aseptic) plant tissue culture process that produces a metabolite
is proven, microbes can still be involved.
Non-taxanes
In a recent short review paper, investigators in Proksch’s group
in Germany gave an excellent summary of the plant-associated
compounds that have now been isolated and reported through
late 2012 from endophytic microbes isolated from the “producing
plant(s).” These included vincristine, camptothecin plus its 9-
methoxy and 10-hydroxy derivatives, podophyllotoxin, hypericin
and its probable biosynthetic precursor, emodin, azadirachtin A
and B and some of the loline alkaloids (Aly et al., 2013).
To this excellent review should be added the following
recent papers covering some of the compounds above and
some unusual findings which give further direct evidence of
fungal involvement. Thus, Ramesha et al. (2013) identified three
endophytic fungi isolated from the fruit and seed regions of the
plant Miquelia dentata Bedd which is reported to have very high
concentrations of camptothecins in its seeds, as Fomitopsis sp.,
Alternaria alternata, and Phomosis sp. What is very intriguing is
that in a paper a year later, the authors reported that, contrary to
what they would have expected, these three fungi were inhibited
by camptothecins, so there may well be negative feedback loops
controlling production (Shweta et al., 2014).
Swainsonine
The relationship between fungal presence and swainsonine
production was first published in 2003 (Braun et al., 2003) and
very interestingly, the fungus, an Undifilum sp., was transferred
by vertical transmission via the seed (Oldrup et al., 2010; Ralphs
et al., 2011). Subsequently, in the last 3 years, three papers
have been published that definitively prove that the compound
swainsonine (Figure 2; 10), the active component of “locoweed,”
is in fact produced by endophytic fungi isolated from the
producing plant. The paper published by Cook et al. (2013)
covered the production of the alkaloid from a fungal endophyte
in the seeds of Ipomoea carnea, and the abolition of production by
treatment of the seeds with a fungicide, but production of other
metabolites such as the calystegnines was unaltered.
Thus, removal of the fungus from the seed abolished
production of the compound but other plant-derived metabolites
were unaltered. This is a rather nice proof of the actual producer
since without the fungus, the germinated plant did not produce
swainsonine.
In the middle of 2013, the same group published details of
the chemistry of swainsonine isolated this time from the original
plant source of the alkaloid, the Australian-sourced Swainsonia
canescens (Grum et al., 2013), and again, an endophytic fungus
closely related to the genus Undifilum was the actual producer.
In 2014, a follow-up paper from the same group (Cook et al.,
2014) covered the production of the alkaloid from a variety of
plant hosts and their associated fungi over wide geographic areas
of the world.
Huperzine
Huperzines A and B (Figure 2; 11, 12) are acetylcholinesterase
inhibitors originally reported as part of Traditional Chinese
Medicine (TCM) (Qin and Xu, 1998) isolated from Huperzia
serrata. Huperzine A was originally synthesized as a racemic
mixture and reported in 1990 with some definition of its
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FIGURE 2 | Compounds from Endophytic Fungi.
pharmacological properties (Kozikowski et al., 1990), and later,
of its binding to acetylcholinesterase (Raves et al., 1997). The
material was launched as a nutraceutical and some clinical trials
are still ongoing.
However, in 2014, two papers were published identifying an
endophytic fungus isolated from H. serrata that produced the
compound (Dong et al., 2014; Shu et al., 2014). The same year,
another group demonstrated the ability of fungal endophytes
also isolated from H. serrata to biotransform huperzine A to
form bioactive sesquiterpenoid hybrids given the trivial name of
Huptremules A–D. All of these hybrids however, were two orders
of magnitude less active as AchE inhibitors compared to the
parent compound (Ying et al., 2014). What is of interest however,
is that these investigators did not discover the producing fungus
referred to above. From the data provided, it is not certain if
plants from the same geographic area were used, or if similar
meteorological conditions applied in each case, as these are
known to affect metabolites found in plants.
Rohutikine
Rohutikine (Figure 2; 13) came into prominence as themodel for
the semisynthetic compound flavopiridol (Figure 2; 14) which
reached Phase II clinical trials in cancer and was heading for
Phase III when Sanofi-Aventis discontinued development. In
2014, flavopiridol was licensed to Tolero Pharmaceuticals in
Utah, USA who are planning to initiate Phase III studies in acute
myelogenous leukemia.
Rohutikine was also the basis for Piramal’s P276-00 (Figure 2;
15) whose status is uncertain due to Piramal’s recent cessation of
small molecule drug discovery, though it was in clinical trials in
the USA for cancer.
Initially the sources of rohutikine were Amoora rohituka
and Dysoxylum binectariferum. It was later reported from
Schumanniophytonmagnificum and S. problematicum. Due to the
therapeutic potential observed for rohutikine derivatives, there
was a search for other producers including endophytes. In 2012
Mohana Kumara et al reported the production of rohutikine by
fermentation of the endophytic fungus Fusarium proliferatum
isolated fromD. binectariferum (Mohana Kumara et al., 2012). In
2014 the same group reported that four other fungal species, three
Fusarium isolates from D. binectariferum and one, Gibberella
fujikuroi isolated from A. rohituka, also produced the compound
on fermentation., They did make the point that the yield dropped
on extended cultivation, though this may be due to the loss of
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as yet unknown co-factors (see discussion earlier on competitive
fermentations and switching on of cryptic clusters) (Mohana
Kumara et al., 2014).
Kaempferol
In a recent paper, Huang et al. (2014) described the isolation
of endophytic fungi from surface sterilized rhizomes of the
high-altitude plant Sinopodophyllum hexandrum Royal collected
in the Taibai Mountains of China. These isolated fungi
produced both podophyllotoxin and kaempferol (Figure 2; 16,
17) on fermentation. The reason for looking at this particular
plant/geographic area was the initial report by Ying (1979)
that this plant produced both of the compounds. One fungus
produced only kaempferol but another identified as Mucor
fragilis Fresen. (Mucoraceae) produced both compounds and was
deposited in the China Center for Type Culture Collection as M
205032. The authors suggested horizontal gene transfer (HGT)
from the plant to the fungus but equally the fungus, under cryptic
cluster control (vide infra), could be the source for the plant to use
as protective agents against attack.
Plant-derived Compounds from
Epiphytes/Endophytes (and/or Root Associated
Microbes)
Due to the differences in definition by multiple authors as to
epiphyte and endophyte, when a compound is reported from
microbes that are not “within” the tissues of the plant we have
discussed them in this section. As information is published, the
actual producer may “move” within these definitions as shown
below for maytansine and the ergot alkaloids.
Maytansine
For many years, maytansine (Figure 3; 18) and congeners were
thought to be exclusively plant-derived secondary metabolites.
Maytansine was first reported by Kupchan et al. (1972) isolated
in very low yield from Maytenus ovatus collected in Ethiopia,
and later isolated fromM. buchananii and Putterlickia verrucosa.
The compound also exhibited anti-parasitic and antimicrobial
activity, and based on maytansine exhibiting potent cytotoxic
activity against humanKB cells, as well as several other cancer cell
lines, researchers became interested in using this pharmacophore
for the treatment of cancer. Though total syntheses were reported
by the Meyers (Meyers and Shaw, 1974) and Corey research
groups (Corey et al., 1980), these syntheses were multi-step, time-
and labor-intensive, and impractical for large-scale synthesis for
clinical trials, so large-scale extraction processes were used to
obtain enough material for clinical trials.
Since maytansine was a 19-membered, halogenated
ansamycin, an unusual structure for a plant secondary
metabolite, but a chemotype that is commonly produced
by eubacteria, and was found to be present in some but not
all individual P. verrucosa plants, a search commenced for
microorganisms (fungal or eubacterial endophytes) that could
produce its core structure.
In 1977, investigators at Takeda Industries in Japan reported
the discovery of ansamitocins P-0, P-1, P-2, P-3 (Figure 3; 19), P-
3′, and P-4, which are maytansine-like derivatives with either an
ester or hydroxyl moiety at C3, from two subspecies of Nocardia
(subsequently renamed as Actinosynenna pretiosum) isolated
from the Carex species of grassy plants (Higashide et al., 1977).
Because the only difference betweenmaytansine and ansamitocin
P-3 is the ester moiety at C3, and none of the biosynthetic genes
leading to the production of maytansine had been found in the
plant host (Yu et al., 2012), researchers speculated that the P-
3 precursor was produced by an endophyte or symbiont in the
rhizosphere, followed by uptake of the bacterial metabolite and
converted into maytansine.
This hypothesis seemed plausible, since several ansamitocins
are produced by eubacteria, higher plants, and mosses,
contradicting the common evolutionary theory that natural
products are produced by taxonomically-related organisms.
Wings and coworkers grew axenic cultures of P. verrucosa and
could not amplify genes involved in maytansine biosynthesis,
and a maytansine-producing eubacterium could not be cultured
outside of its natural habitat (Wings et al., 2013). By using
molecular techniques such as rDNA sequencing and single
strand conformation polymorphism, they identified that the
A. pretiosum ssp. auranticum eubacterium present in the
rhizosphere of the plant is involved in maytansine biosynthesis.
Whether this is an epiphyte or a root-associate endophyte is not
yet fully elucidated.
FIGURE 3 | Compounds from Epiphytic and “Endophytic” Microbes.
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Based on rDNA sequence analysis, the A. pretiosum ssp.
auranticum eubacterium had the identical 16S rDNA sequence
as that amplified from the DNA of a maytansine-producing
P. verrucosa plant (Wings et al., 2013). Other non-maytansine
producing P. verrucosa plants lacked this 16S rDNA sequence.
These data are consistent with the absence of maytansine in cell
cultures derived from maytansine-producing P. verrucosa plants
as well as greenhouse grown Maytenus sp., and Putterlickia sp.,
plants and their corresponding cell cultures (Wings et al., 2013).
Mounting evidence has shown that the microorganisms in the
rhizosphere of plants in different environments as well as those
in non-rhizosphere communities in the surrounding soil appear
to differ (Gunatilaka, 2006). This may explain why maytansine
is found in mosses and higher plants. However, nominally
ansamitocin-producing plants have been speculated to contribute
to the structural diversity of ansamitocins via infection of their
root system because only two known ansamitocins have been
found in eubacteria, while there are 22 known in plants (Wings
et al., 2013).
In 2014, the debate as to whether the ansamitocin derivatives
produced in the rhizosphere were subsequently transported into
the plant and then trans-esterified to produce maytansine from
ansamitocin P3, was decided in favor of the production of
maytansine by a consortium of microbes in the rhizosphere of
the plants Putterlickia verrucosa and P. retrospinosa, though the
exact organism(s) performing the reaction are not yet identifiable
(Kusari et al., 2014c). Thus, the materials found in specific areas
may well be the products of multiple interactions outside of and
within the “nominal plant producer.”
Ergot Alkaloids
There is one well defined series of compounds that are considered
to be produced via epiphytes that has been known for centuries;
the production of the ergot alkaloids such as lysergic acid α-
hydroxyethylamide (Figure 3; 20) due to the contamination of
rye by the fungus Claviceps purpurea.
In a recent publication, Beaulieu et al reported on the
expansion of biosynthetic capabilities beyond Claviceps species,
including bacterial and fungal symbionts depending upon the
host plant (Beaulieu et al., 2013). What is significant, though it
had been known for a reasonable amount of time, was the vertical
transmission of the epiphyte in the seeds of the infected plant, and
they described the allocation of these alkaloids during the early
ontology of Morning Glory plants (Ipomoea species), though the
fungus in these cases was close to a Periglandula-like species.
As mentioned earlier in this review, I. carnea was reported to
produce swainsonine via a vertically transmitted microbe as well.
In 2014, Hodgson et al. (2014) reported that vertical
transmission of fungal endophytes is widespread in “forbs” (also
known as herbs or Phorbs) which are defined by the USDA
(United States Department of Agriculture) as:
“Vascular plant without significant woody tissue above or at the
ground. Forbs and herbs may be annual, biennial, or perennial
but always lack significant thickening by secondary woody growth
and have perennating buds borne at or below the ground surface.
In plants, graminoids are excluded but ferns, horsetails, lycopods,
and whisk-ferns are included. (http://plants.usda.gov/growth_
habits_def.html)”
Thus, the phenomenon of such vertical transmission is not
rare but an integral part of how a plant may recruit defensive
measures. As to whether these are co-evolution, horizontal
gene transfer or mutualistic survival methodologies, one can
make a choice, but it is now becoming quite evident that such
interactions between plants and microbes are very common and
not rare occurrences.
Compounds from Fungal-Bacterial
Interactions
Rhizoxin and Derivatives
Rhizoxin (Figure 4; 21) was reported in 1984 by Iwasaki et al.
(1984) from a Rhizopus species that caused rice blight and its
antitumor activity was then reported by Tsuruo et al. (1986). It
entered clinical trials as a tubulin interactive agent but did not
proceed beyond Phase II due to a lack of significant responses in
patients (Hanauske et al., 1996).
Many chemists used total synthesis to make rhizoxin and
several derivatives (Nakada et al., 1993; Hong and White, 2004).
In the early 2000s, Partida-Martinez and Hertweck began to
investigate the biosynthesis of the compound in Rhizopus via
fermentation, and rapidly discovered that rhizoxin was not
a fungal metabolite, but rather a product of an eubacterial
FIGURE 4 | Compounds from Fungal-endophytic Bacterial Association.
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endosymbiont Burkholderia sp. On isolation and purification of
this bacterium, they demonstrated that the organism contained
the biosynthetic genes involved in the production of rhizoxin
(Partida-Martinez and Hertweck, 2005, 2007).
These observations were consistent with four Rhizopus species
producing rhizoxin and two species that did not, when collected
in diverse geographical areas. Furthermore, laser microscopic
observations of Rhizopus sp. mycelium stained with a mixture
of bacteria-specific dyes revealed the appearance of a high
number of live endosymbiotic eubacteria within fungal cells.
Notably, when Rhizopus sp. was cultured in the absence of
the Burkholderia endosymbiont, rhizoxin was not produced.
However, when the Burkholderia sp. was isolated from the
fungus and cultured in the absence of Rhizopus sp., rhizoxin
and potent cytotoxic derivatives (1000–10,000 times more active
against K-562 leukemia cells) were produced (Scherlach et al.,
2006). Interestingly, the isolated eubacterial endosymbiont lost
its ability to produce these metabolites over time, but rhizoxin
increased upon the reintroduction of Rhizopus sp. into cultures.
The authors speculated that the decrease in rhizoxin was most
likely due to the down-regulation of its biosynthetic genes in the
absence of Rhizopus sp.
Deletion of a Burkholderia p450 gene involved in rhizoxin
biosynthesis produced di-desepoxy rhizoxin derivatives, but
whether this gene was involved in catalyzing the formation of
both epoxide moieties in rhizoxin was unclear (Scherlach et al.,
2012). The epoxidation steps were also determined to be oxygen
independent.
To elucidate the biosynthetic steps required to install the
epoxide moieties, the authors used two different Burkholderia-
Rhizopus associations from different regions of the world
that either produced rhizoxin or the monoepoxide derivative
WF-1360F (Figure 4; 22). Using these combinations, they
“switched” the symbiotic associations by cross-infecting each
endosymbiotic-freeR.microporus fungus with the endosymbiotic
eubacterium of the other fungus. Interestingly, the symbiotic
association that previously produced rhizoxin produced WF-
1360F, whereas the other association produced rhizoxin. Thus,
these results led the authors to revise their proposed mechanism
of rhizoxin biosynthesis in the 2005 Nature paper (Partida-
Martinez and Hertweck, 2005).
These events are most likely triggered by chemical signals.
These are probably produced via the symbiotic phytotoxin
production resulting from the strain-specific association of
Burkholderia sp. and Rhizopus sp.. In addition, these may be
further influenced by plant interactions upon infection of the rice
seedlings.
Thus, the vertically transmitted eubacterial intracellular
symbiont of Rhizopus sp. delivers WF-1360F to the host fungus,
which is then involved in catalyzing the epoxidation of the WF-
1360F to give rhizoxin. This is a more potent phytotoxin that
plays an essential role in the vegetative spore formation of the
fungus containing the endosymbiont, most likely for colonizing
rice (Partida-Martinez et al., 2007). In this unparalleled tripartite
relationship, both the pathogenic fungus and endosymbiont
benefit by gaining access to nutrients that are released once the
phytopathogenic fungus colonizes the roots of Oryza sativa.
Insect-Microbe Interactions
We will discuss two of the many potential examples of this type
of interaction. Though many are postulated, in the two examples
given, the interactions have been characterized as harnessing
the metabolites produced as protective factors of benefit to the
arthropod hosts.
Dentigerumycin Production
The seminal work published on dentigerumycin (Figure 5; 23)
by Oh and coworkers, demonstrated how fungus-growing ants
and actinobacteria work together to produce a specific toxin
that specifically eliminates specialized fungal parasites (Oh et al.,
2009a). In 2001, the eubacterium Pseudonocardia sp., fungal
isolates (used as a food source for these attine ants), and
FIGURE 5 | Compounds from Microbe-Insect Association.
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the parasitic fungus Escovopsis sp. were isolated from the nest
of the ant Apterostigma dentigerum in Gamboa, Panama. The
Pseudonocardia sp., isolated from the ant cuticle, was observed
to strongly inhibit Escovopsis sp. from the same ant colony, while
the fungal isolates were resistant to this bacterium.
The active component isolated from the Pseudonocardia
sp. was the depsipeptide dentigerumycin, which contained
highly unusual amino acid residues, such as piperazic acid,
γ-hydroxypiperazic acid, β-hydroxyleucine, N-hydroxyleucine,
and a polyketide-derived side chain linked to a pyran ring.
Dentigerumycin inhibited the growth of the Escovopsis sp., as well
as Candida albicans strains, including the amphotericin-resistant
version ATCC200955, in liquid culture assays.
Thus, the symbiosis between Pseudonocardia sp. and fungus-
farming ants is an example of novel ways ants have evolved to
protect the fungal cultivar from “garden parasites.” Notably, the
authors speculated that the eubacterial mediator Pseudonocardia
sp. and the fungus Escovopsis sp. will undergo antagonistic
coevolution, such that new eubacterial metabolites will target
resistant Escovopsis sp. Such evolutionary processes may well
play major roles in the continuous production of new, diverse
secondary metabolites from mutualistic interactions.
Mycangimycin Production by Beetle Symbionts
Scott and coworkers reported the existence of chemically-
mediated protection supplied by a eubacterial source against
the fungal antagonist, Ophiostoma minus, of the fungal food
source (Entomocorticium sp. A) required for the development
of Southern pine beetle (Dendroctonus frontalis) larvae (Scott
et al., 2008). Adult beetles harbor Entomocorticium sp. A in
a specialized compartment, make holes in the barks of trees,
deposit larvae within the bark and phloem of trees, and inoculate
them with this fungus. This process can be challenged by a
parasitic fungus that can outcompete Entomocorticum sp. A,
ultimately disrupting beetle larvae development.
As part of the beetle’s defense mechanism, its specialized
compartment harboring food is also a source of different species
of actinomycetes, which are also deposited with Entomocorticum
sp. A. The authors were able to demonstrate the antifungal
activity of one actinomycete morphotype against O. minus with
an MIC of 1.0µM, which was 19 times more susceptible than
Entomocorticum sp. A (MIC, 19.0µM). The active antifungal
agent was determined to be the linear 20-carbon polyunsaturated
peroxide, mycangimycin (Figure 5; 24) (Oh et al., 2009b). This
compound also exhibited potent antifungal activity against C.
albicans, C. albicans ATCC 10231, C. albicans ATCC 200955, and
Saccharomyces cerevisiae, with MIC values ranging between 0.7
and 1.4µM. The following year, there was a report of a free-living
actinomycete producing the same material from an Egyptian soil
sample (Atta, 2010).
The basic scaffold of mycangimycin resembles those of
some known antimalarial agents, and when assayed against
Plasmodium falciparum, the compound exhibited antimalarial
activity with an EC50 of 17 ng/ml, which is comparable to other
antimalarial drugs with EC50 values close to 10 ng/ml. More
studies need to be completed to determine the mechanism
of action of mycangimycin, as well as whether it possesses
other biological properties. However, this is a good example of
how specialized small molecules that serve as mediators within
mutualistic interactions can also function as new therapeutics.
In Conclusion
In this short review, we have attempted to demonstrate that in
all kingdoms of life, microbes may play a role in the production
of secondary metabolites in “higher hosts.” Does this mean that
we are saying that “ALL secondary metabolites irrespective of the
higher host are microbial in origin”? The current answer overall
is NO for plants, but in the marine environment, the pendulum
may well be swinging toward “YES.”
With the recognition of chalcone synthases being present
in marine microbes, it might be of interest to note that 262
terpene synthase genes have recently been identified from
terrestrial microbial genome sequences by workers at the Kitasato
Institute and we have inserted their conclusions in the following
paragraph.
“Terpenes are generally considered to be plant or fungal
metabolites, although a small number of odoriferous terpenes
of bacterial origin have been known for many years. Recently,
extensive bacterial genome sequencing and bioinformatic analysis
of deduced bacterial proteins using a profile based on a hidden
Markov model have revealed 262 distinct predicted terpene
synthases. Although many of these presumptive terpene synthase
genes seem to be silent in their parent microorganisms, controlled
expression of these genes in an engineered heterologous
Streptomyces host hasmade it possible to identify the biochemical
function of the encoded terpene synthases. Genes encoding such
terpene synthases have been shown to be widely distributed in
bacteria and represent a fertile source for discovery of new natural
products” (Yamada et al., 2015).
Thus, can one now claim that terpene synthases and chalcone
synthases are all from eukaryotes in the future?
However, when one investigates the relationships between
hosts and microbes in marine and terrestrial environments, it is
striking that the types of interaction, in particular those leading
to secondary metabolites are many and complex. They are not
as simple as saying that “X” is a plant metabolite and “Y”
comes from a marine invertebrate. Yes, each was isolated from a
specific “host” but the question as to what combination of events
produced the compound is no longer simple to answer.
Investigators have to take into account that as yet uncultivated
microbes are probably the major sources of these interactions,
and that simple culturing techniques may not be adequate to
identify the range of potential interactions. It is not a one
host/one microbe style of interaction but probably involves many
interactions between microbes and the host, not just a simple
one to one relationship. When one then has to consider “cryptic
gene clusters and their control (cf the terpene synthase discussion
above).”
What has to also be recognized, and it is alluded to in
some of the examples given above, is that in Nature, microbes
are not “singletons,” they are part of essential consortia. Many
examples are available to demonstrate this, with one being
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the mixed cultures inside a very protective biofilm that is the
essential part of the metabolism of phosphates in sewage plants.
Similar collections of microbes are present in soils and marine
invertebrates, and also in vertebrates in general, as all one has to
do is to look at the information now appearing on the human
microbiome.
To finish and to give an idea of the magnitude of the
processes potentially involved, the very recent review by Charlop-
Powers et al. (2015) should be consulted to see the magnitude
of secondary metabolites that are potentially present, and
then to think of the vast number of interactions, yet to be
discovered.
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